Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance https://www.biorxiv.org/content/10.1101/2023.01.23.525210v1?med=mas
Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance https://www.biorxiv.org/content/10.1101/2023.01.23.525210v1?med=mas